Cost-effectiveness analysis (CEA) of seven treatment regimens in metastatic hormone-sensitive prostate cancer (mHSPC): A public payer perspective using network meta-analysis. Development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback